What do systematic reviews say?

Probenecid vs allopurinol

The review found no eligible studies for this question.

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Benzbromarone vs allopurinol

Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  RR 1.25 [0.28, 5.62]
  2 studies · 91 participants
  Low

Benzbromarone vs allopurinol

Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  RR 3 [0.64, 14.16]
  1 study · 55 participants
  Low

Benzbromarone vs allopurinol

The review found no eligible studies for this question.

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Benzbromarone vs allopurinol

The review found no eligible studies for this question.

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Benzbromarone vs allopurinol

The review found no eligible studies for this question.

• Uricosuric medications for chronic gout 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ciprofloxacin vs fluoroquinolones

It is very uncertain whether ciprofloxacin changes clinical efficacy ‐ cure or improvement at end of treatment compared with comparator fluoroquinolone (very low certainty).

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 0.9 [0.75, 1.08]
  3 studies · 851 participants
  Very low
• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 0.93 [0.72, 1.2]
  3 studies · 851 participants
  Very low

Ciprofloxacin vs fluoroquinolones

Ciprofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 1.16 [0.95, 1.42]
  3 studies · 967 participants
  Moderate

Levofloxacin vs fluoroquinolones

It is very uncertain whether levofloxacin changes microbiological efficacy ‐ pathogen eradication compared with comparator fluoroquinolone (very low certainty).

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 1.12 [0.84, 1.48]
  3 studies · 758 participants
  Very low

Levofloxacin vs fluoroquinolones

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Levofloxacin vs fluoroquinolones

Levofloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 0.88 [0.72, 1.08]
  3 studies · 874 participants
  Moderate

Lomefloxacin vs fluoroquinolones

Lomefloxacin showed no clear difference in microbiological efficacy ‐ pathogen eradication at compared with comparator fluoroquinolone (low certainty).

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 0.96 [0.8, 1.16]
  2 studies · 116 participants
  Low

Lomefloxacin vs fluoroquinolones

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Lomefloxacin vs fluoroquinolones

Lomefloxacin showed no clear difference in adverse effects of treatment ‐ any adverse effects compared with comparator fluoroquinolone (moderate certainty).

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 0.64 [0.34, 1.21]
  2 studies · 215 participants
  Moderate

Ciprofloxacin vs fluoroquinolones

It is very uncertain whether ciprofloxacin changes microbiological efficacy ‐ pathogen eradication at end of treatment compared with comparator fluoroquinolone (very low certainty).

• Antimicrobial therapy for chronic bacterial prostatitis 2013 · Cochrane Headline outcomes only
  RR 0.91 [0.7, 1.18]
  3 studies · 851 participants
  Very low

Betamethasone oral mini-pulse therapy vs Topical triamcinolone acetonide paste

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  Table 3 (Side-effects). Malhotra 2008: betamethasone oral mini-pulse - transient oedema over the face (7), oedema over hands and feet (4), epigastric discomfort (7), weakness/fatigue (5), loose stools (1), headache…
  1 study · 22 participants
  GRADE not reported

Doxycycline+Rifampicin vs Quinolones+Rifampicin

Doxycycline+Rifampicin showed no clear difference in total treatment failure compared with quinolones+Rifampicin (moderate certainty).

• Antibiotics for treating human brucellosis 2012 · Cochrane Headline outcomes only
  OR 0.94 [0.45, 1.98]
  3 studies · 181 participants
  Moderate

Febuxostat 40 mg/day vs allopurinol

Febuxostat 40 mg/day showed no clear difference in incidence of gout flares compared with allopurinol (high certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 0.97 [0.57, 1.65]
  1 study · 1324 participants
  High

Febuxostat 40 mg/day vs allopurinol

Febuxostat 40 mg/day showed no clear difference in serum uric acid <6.0 mg/dL at final visit compared with allopurinol (moderate certainty).

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  RR 1.1 [0.94, 1.2]
  1 study · 1324 participants
  Moderate

Febuxostat 40 mg/day vs allopurinol

The review found no eligible studies for this question.

• Febuxostat for treating chronic gout 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found